Therefore, we assume that a cytokine signature including several potent individual cytokines (i.e., Il-6, IL-1RA, and IL-10) in addition to the standard laboratory markers might be a more useful tool in the stratification of patients with COVID-19 and CCS that will benefit from the immunomodulatory therapy. The gene discussed is IL10; the disease is COVID-19.